Additional alternative therapeutic approaches are based on combination of TLR4 agonist as a vaccine adjuvant with tumor-associated antigens in combination with radio- or chemotherapy or autologous dendritic cell therapy. This evidence concerns the gene TLR4 and neoplasm.